



(51) International Patent Classification:

C07K 14/375 (2006.01) C07K 7/08 (2006.01)
A61P 7/06 (2006.01) C07K 14/575 (2006.01)
C07K 7/06 (2006.01)

Bachulal; 587 Torland Court, Sunnyvale, California 94087 (US). **VALONE, Frank Horace**; c/o Protagonist Therapeutics, Inc., 7707 Gateway Boulevard, Suite 140, Newark, California 94560 (US).

(21) International Application Number:

PCT/US2022/033378

(74) **Agent: LAHERTY, Carol et al.**; Cooley LLP, 1299 Pennsylvania Ave., NW, Suite 700, Washington, District of Columbia 20004 (US).

(22) International Filing Date:

14 June 2022 (14.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/210,453 14 June 2021 (14.06.2021) US
63/252,001 04 October 2021 (04.10.2021) US
63/349,841 07 June 2022 (07.06.2022) US

(71) **Applicant: PROTAGONIST THERAPEUTICS, INC.**
[US/US]; 7707 Gateway Boulevard, Suite 140, Newark, California 94560 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(72) **Inventors: GUPTA, Suneel Kumar**; 1331 Elsona Drive, Sunnyvale, California 94087 (US). **LIU, David Y.**; c/o Protagonist Therapeutics, Inc., 7707 Gateway Boulevard, Suite 140, Newark, California 94560 (US). **MODI, Nishit**

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: HEPCIDIN MIMETICS FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS




FIG. 1

(57) **Abstract:** The disclosure provides methods for the treatment and/or prevention of iron overload diseases such as hereditary hemochromatosis.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*